Effects of ACEIs versus ARBs on proteinuria or albuminuria in primary hypertension: A meta-Analysis of randomized trials

Medicine (United States)

Volumn 94, Issue 39, 2015, Pages e1560-

  Xu, Rui ^a   Sun, Shanmei ^a,b   Huo, Yan ^a,b   Yun, Lin ^a   Huang, Shuai ^a,b   Li, Guohua ^a   Yan, Suhua ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ANTIHYPERTENSIVE AGENT;

ALBUMINURIA; ARTICLE; BLOOD PRESSURE REGULATION; COUGHING; CREATININE URINE LEVEL; DIABETES MELLITUS; DRUG EFFICACY; FOLLOW UP; HEADACHE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH PAIN; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; BLOOD PRESSURE; DRUG EFFECTS; FEMALE; MALE; PATHOPHYSIOLOGY;

ALBUMINURIA; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; FEMALE; HUMANS; HYPERTENSION; MALE; PROTEINURIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84943191550     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000001560     Document Type: Article

References (35)

1. Yano Y, Fujimoto S, Kramer H, et al. Long-term blood pressure variability, new-onset diabetes mellitus, and new-onset chronic kidney disease in the Japanese general population. Hypertension. 2015;66:30-36.
2. Sim JJ, Jiaxiao Si, Kovesdy CP, et al. Impact of achieved blood pressures on mortality risk and end-stage renal disease among a large, diverse hypertension population. J Am Coll Cardiol. 2014;64:588-597.
3. James PA1, Oparil S2, Carter BL1, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507-520.
4. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-Analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
5. Engels EA, Schmid CH, Terrin N, et al. Heterogeneity and statistical significance in meta-Analysis: an empirical study of 125 metaanalyses. Stat Med. 2000;19:1707-1728.
6. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5:13.
7. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
8. Takagi H, Yamamoto H, Iwata K, et al. Effects of telmisartan on proteinuria or albuminuria: a meta-Analysis of randomized trials. Int J Cardiol. 2013;167:1443-1449.
9. Sengul AM, Altuntas Y, Kurklu A, et al. Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria, and hypertension. Diabetes Res Clin Pract. 2006;71:210-219.
10. Tan F, Mukherjee JJ, Lee KO, et al. Dual blockade of the reninangiotensin-Aldosterone system is safe and effective in reducing albuminuria in Asian type 2 diabetic patients with nephropathy. Singapore Med J. 2010;51:151-156.
11. Fernandez Juarez G, Luno J, Barrio V, et al. Effect of dual blockade of the renin-Angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial. Am J Kidney Dis. 2013;61: 211-218.
12. Deyneli O, Yavuz D, Velioglu A, et al. Effects of ACE inhibition and angiotensin II receptor blockade on glomerular basement membrane protein excretion and charge selectivity in type 2 diabetic patients. J Renin Angiotensin Aldosterone Syst. 2006;7: 98-103.
13. Lacourciere Y, Belanger A, Godin C, et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int. 2000;58:762-769.
14. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547-553.
15. Zhu S, Liu Y, Wang L, et al. Transforming growth factor-beta1 is associated with kidney damage in patients with essential hypertension: renoprotective effect of ACE inhibitor and/or angiotensin II receptor blocker. Nephrol Dial Transplant. 2008;23: 2841-2846.
16. Scaglione R, Argano C, Corrao S, et al. Transforming growth factor beta1 and additional renoprotective effect of combination ACE inhibitor and angiotensin II receptor blocker in hypertensive subjects with minor renal abnormalities: a 24-week randomized controlled trial. J Hypertens. 2005;23:657-664.
17. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-Angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000;321:1440-1444.
18. Ogawa S, Takeuchi K, Mori T, et al. Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy. Hypertens Res. 2007;30:325-334.
19. Luno J, Barrio V, Goicoechea MA, et al. Effects of dual blockade of the renin-Angiotensin system in primary proteinuric nephropathies. Kidney Int Suppl. 2002;82:S47-S52.
20. Nakamura T, Kawachi K, Saito Y, et al. Effects of ARB or ACEinhibitor administration on plasma levels of aldosterone and adiponectin in hypertension. Int Heart J. 2009;50:501-512.
21. Liu AG, Xu DY, Wang X, et al. Effects of losartan and enalapril on the renal function in old patients with hypertension. J Binzhou Med Coll. 2004;27:184-185.
22. Liu H, Hao JH, Xiang Q. Effects of angiotensin II receptorantagonist on renal function in patients with elderly essential hypertension. Chinese J Pract Internal Med. 2000;20:475-477.
23. Dang LJ. Comparative research on ACEI and ARB for hypertension. Chinese J Med Guide. 2012;07:1196-1202.
24. Li HL, He WS. The curative effect of losartan or benazepril on patients with essential hypertension combined with nephropathy complicated by type 2 diabetes mellitus. Guide China Med. 2008;20:055-063.
25. Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351:1952-1961.
26. MacGregor MS, Taal MW. Renal Association Clinical Practice Guideline on detection, monitoring and management of patients with CKD. Nephron Clin Pract. 2011;118(Suppl 1):c71-c100.
27. Upadhyay A, Earley A, Haynes SM, et al. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med. 2011;154:541-548.
28. KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3:19.
29. Gonzalez-Albarran O, Garcia Robles R, Ruilope LM. Therapeutic implications and new perspectives for essential hypertension and renal damage. Kidney Int Suppl. 1998;68:S46-S50.
30. von Lueder TG, Krum H. RAAS inhibitors and cardiovascular protection in large scale trials. Cardiovasc Drugs Ther. 2013;27:171-179.
31. Li CJ, Bu PL. Meta-Analysis of efficacy of ACEI and ARB in treatment of proteinuria in essential hypertension. Med Recapitulate. 2012;17:2872-2884.
32. Kunz R, Friedrich C, Wolbers M, et al. Meta-Analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008;148:30-48.
33. Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens. 1993;11:309-317.
34. Cheng J, Zhang W, Zhang X, et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-Analysis. JAMA Intern Med. 2014;174:773-785.
35. van Vark LC, Bertrand M, Akkerhuis KM, et al. Angiotensinconverting enzyme inhibitors reduce mortality in hypertension: a metaanalysis of randomized clinical trials of renin-Angiotensin-Aldosterone system inhibitors involving 158,998 patients. Eur Heart J. 2012;33: 2088-2097.